Table 1 The characteristics of the study patients and temporal trends for 7 years

Patients number

1263

195

162

210

184

188

189

135

Age, years

64.5 ± 14.0

60.2 ± 14.8

63.5 ± 12.9

63.5 ± 14.1

65.9 ± 14.1

64.8 ± 13.5

67.8 ± 13.3

66.6 ± 13.9

.000

Male, %

65

65

65

68

63

68

60

64

.722

Diabetes, %

46

50

48

43

51

44

42

45

.517

BMI, kg/m²

23.1 ± 4.7

22.6 ± 5.5

23.1 ± 3.9

22.7 ± 3.4

23.1 ± 4.5

23.7 ± 6.4

22.9 ± 4.6

23.8 ± 4.2

.212

Duration of nephrologist care, days

625

552

432

608

566

697

796

775

.109

[174, 1557]

[83, 1789]

[175, 1450]

[185, 1346]

[138, 1356]

[160, 1860]

[206, 1530]

[254, 1827]

Vascular access, %

70

68

70

70

69

68

68

77

.615

.000

Diabetic nephropathy

44

47

48

42

47

43

40

40

Glomerulonephritis

21

31

17

25

15

18

18

23

Nephrosclerosis

16

7

17

10

19

19

25

22

PCK

4

2

5

4

3

5

5

2

Others

16

14

14

20

17

16

13

13

Systolic BP, mmHg

155 ± 25

152 ± 25

159 ± 24

154 ± 25

153 ± 26

155 ± 25

154 ± 23

156 ± 25

.222

Diastolic BP, mmHg

78 ± 14

77 ± 13

80 ± 14

79 ± 13

76 ± 14

79 ± 14

78 ± 14

81 ± 14

.067

CTR, %

53.3 ± 6.7

52.6 ± 6.5

53.9 ± 6.3

53.4 ± 6.9

53.7 ± 6.6

53.5 ± 6.4

52.9 ± 7.9

53.2 ± 6.2

.659

Hemoglobin, g/dL

8.7 ± 1.5

8.5 ± 1.6

8.6 ± 1.3

8.6 ± 1.6

8.7 ± 1.4

8.6 ± 1.5

9.0 ± 1.5

9.1 ± 1.4

.002

Hemoglobin/dose of ESA^a

0.46

0.48

0.43

0.43

0.58

0.58

0.46

0.40

.050

[0.35, 0.72]

[0.35, 0.71]

[0.35, 0.70]

[0.35, 0.69]

[0.38, 0.77]

[0.38, 0.73]

[0.33, 0.76]

[0.27, 0.73]

Albumin, g/dL

3.3 ± 0.5

3.3 ± 0.5

3.3 ± 0.5

3.4 ± 0.5

3.3 ± 0.5

3.3 ± 0.5

3.4 ± 0.5

3.4 ± 0.5

.153

Creatinine, mg/dL

9.4 ± 3.2

9.8 ± 3.8

9.7 ± 3.5

9.1 ± 2.9

9.4 ± 3.2

9.1 ± 3.1

9.3 ± 3.1

9.6 ± 3.0

.228

eGFR, mL/min/1.73²

5.1 ± 2.2

5.2 ± 2.2

5.0 ± 1.9

5.4 ± 2.1

5.2 ± 2.9

5.3 ± 1.8

5.0 ± 1.9

4.8 ± 1.9

.280

Total cholesterol, mg/dL

172 ± 50

177 ± 53

180 ± 53

170 ± 47

170 ± 42

169 ± 56

171 ± 52

168 ± 44

.401

Triglyceride, mg/dL

111

113

110

106

114

103

126

109

.272

[81, 157]

[80, 156]

[79, 167]

[79, 201]

[81, 152]

[76, 161]

[88, 163]

[83, 149]

HDL-C, mg/dL

48 ± 16

49 ± 18

50 ± 19

48 ± 15

46 ± 14

49 ± 17

49 ± 16

46 ± 15

.223

Calcium, mg/dL

7.8 ± 0.9

7.8 ± 1.0

7.8 ± 1.0

7.9 ± 0.9

7.8 ± 0.9

7.8 ± 0.9

8.0 ± 0.9

7.8 ± 0.9

.092

Phosphate, mg/dL

6.1 ± 1.6

6.1 ± 1.6

5.9 ± 1.5

5.9 ± 1.4

6.1 ± 1.7

6.1 ± 1.5

6.0 ± 1.6

6.4 ± 1.5

.045

Ca x P product

47 ± 13

47 ± 13

46 ± 13

46 ± 12

46 ± 14

47 ± 12

48 ± 14

49 ± 15

.260

i-PTH, pg/mL

271

210

264

300

285

272

266

331

.000

[169, 414]

[141, 346]

[179, 382]

[170, 425]

[185, 416]

[171, 426]

[159, 393]

[188, 468]

CRP, mg/dL

0.10

0.10

0.10

0.10

0.08

0.10

0.10

0.13

.000

[0.04, 0.17]

[0.04, 0.15]

[0.0, 0.14]

[0.0, 0.13]

[0.02, 0.10]

[0.02, 0.20]

[0.05, 0.20]

[0.05, 0.20]

Glucose, mg/dL

137 ± 52

142 ± 61

144 ± 61

135 ± 47

136 ± 53

137 ± 49

130 ± 47

139 ± 44

.243

Fe, μg/dL

67 ± 35

66 ± 36

64 ± 31

69 ± 33

68 ± 33

70 ± 37

66 ± 35

66 ± 39

.772

TIBC, μg/dL

233 ± 46

229 ± 46

239 ± 41

236 ± 51

229 ± 49

230 ± 48

231 ± 42

236 ± 43

.352

Ferritin, ng/dL

117

117

111

141

110

124

126

101

.309

[57, 209]

[61, 199]

[56, 194]

[68, 232]

[51, 114]

[57, 225]

[56, 213]

[42, 187]

ESA, %

78

81

74

77

79

79

80

80

.810

long-acting ESA, %

15

0

0

0

0

2

49

80

.000

Dose of ESA, per month

12,000

12,000

12,000

24,000

12,000

12,000

24,000

24,000

.001

[12,000, 24,000]

[12,000, 24,000]

[12,000, 24,000]

[12,000, 24,000]

[12,000, 24,000]

[12,000, 24,000]

[12,000, 24,000]

[12,000, 33,000]

ARB/ACE-I, %

64

56

67

69

61

70

65

61

.051

Vitamin D, %

31

26

34

271

23

36

32

41

.007

AST-120, %

19

17

18

27

19

19

16

14

0.054

Iron, %

19

31

18

20

18

14

23

19

.403